Request Demo
Recent blog posts
Latest Hotspot
8 min read
Ensereptide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Ensereptide: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Velzatinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Velzatinib: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Azetukalner Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Azetukalner: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Rilvegostomig Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Rilvegostomig: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Tividenofusp alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Tividenofusp alfa: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Nivadstrocel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Nivadstrocel: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
lunsotogene parvec-cwha Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
lunsotogene parvec-cwha: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Motugivatrep Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Motugivatrep: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Copper Histidine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Copper Histidine: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Sosimerasib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Sosimerasib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Risovalisib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Risovalisib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Sepetaprost Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Sepetaprost: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.